HopeStage
Back to all studies
TerminatedNCT05260541

A Clinical Trial of PRAX-114 in Participants With PTSD

Researchers are comparing 60 mg PRAX-114 or 40 mg PRAX-114, 40 mg PRAX-114 and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Medication studyAges 18–65United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing 60 mg PRAX-114 or 40 mg PRAX-114, 40 mg PRAX-114 and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Who could participate?

This study is for people with PTSD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Phoenix and 16 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 25, 2022
Recruitment status
Terminated
Enrollment listed in the registry
11
Sponsor
Praxis Precision Medicines
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05260541
Official title
Show the full official title

A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Recruitment & locations

Terminated

Phoenix · Little Rock · Rogers

14 more locations
  • Lemon Grove
  • Westlake Village
  • Fort Myers
  • Decatur
  • Boston
  • Las Vegas
  • Cincinnati
  • Dayton
  • Oklahoma City
  • Allentown
  • Media
  • Austin
  • Dallas
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing 60 mg PRAX-114 or 40 mg PRAX-114, 40 mg PRAX-114 and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Who is behind this study?

The study sponsor is Praxis Precision Medicines, a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including 60 mg PRAX-114 or 40 mg PRAX-114, Placebo and 40 mg PRAX-114.

Who can participate?

This study is for people with PTSD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies